secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cardiff Oncology, Inc. (CRDF)
CIK:        0001213037
Form:       8-K
Filed at:   2022-04-08T23:59:59+00:00
Accession:  0001628280-22-008804
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cardiff Oncology announces updated Phase 2 mCRPC data and preclinical ovarian cancer data for onvansertib
--------------------------------------------------------------------------------

- Arm C (12 mg/m2 onvansertib days 1-14) achieved 75% radiographic stable disease at 12 weeks vs 53% in Arm A.
- Median progression-free survival increased from 4.1 months in Arm A to 13.2 months to-date in Arm C.
- Combination of onvansertib with olaparib overcame PARP inhibitor resistance in BRCA1-mutant and wildtype PDX ovarian cancer models.
- Mutations in PTEN and MTOR were positively associated with treatment response in mCRPC trial patients.
- Disease control by PSA stabilization improved from 29% in Arm A to 45% in Arm C.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1213037/000162828022008804/0001628280-22-008804-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1213037/000162828022008804/crdf-20220408.htm
  HTML page:      https://secwatch.observer/filing/0001628280-22-008804

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer